| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Moderna Inc. | mRNA-1273.214 | Bivalent booster COVID-19 vaccine | Phase 2/3 | Data Released | Intramuscular | COVID-19 |
| Moderna Inc. | mRNA-1273 - (KidCOVE) | COVID-19 vaccine - pediatric | Phase 2/3 | Ongoing | Intramuscular | COVID-19 |
| Moderna Inc. | mRNA-1893 | Zika virus vaccine | Phase 2 | Ongoing | Intramuscular | N/A |
| Moderna Inc. | VEGF-A (AZD8601) - (EPICCURE) | Heart Failure | Phase 2a | Data Released | Intradermal | Cardiology |
| Molecular Partners AG | Ensovibep (VIR-7831 / GSK4182136) - (ACTIV-3) | Mild to moderate COVID-19 | Phase 3 | Withdrawn | Intravenous | COVID-19 |
| Molecular Partners AG | Ensovibep - (EMPATHY) | COVID-19 | Phase 2/3 | Intravenous | COVID-19 | |
| Molecular Partners AG | MP0250 | Phase 2 | Intravenous | #ERROR: Missing required arguments value for function GPT_CLASSIFY. | ||
| Molecular Partners AG | Ensovibep | COVID-19 | Phase 2a | Intravenous | COVID-19 |